Noom for Women: Safety Record, Regulation, and What the Evidence Actually Shows

Is Noom Legitimate? Cutting Through the Marketing

Noom is a real company, founded in 2008, headquartered in New York, and operating across multiple countries. It is not a scam in the sense of taking money without delivering a product. What you get is an app built around cognitive-behavioral principles, daily lessons, food logging, a personal coach (delivered largely via chat), and, since 2023, access to GLP-1 weight-loss medications through its Noom Med telehealth service.

"Legitimate" and "well-evidenced" are two different things.

The platform has faced meaningful regulatory scrutiny. In 2023 the Federal Trade Commission reached a $62 million settlement with Noom over allegations that the company made it unreasonably difficult to cancel subscriptions and enrolled users in auto-renewing plans without adequate disclosure. Noom did not admit wrongdoing, but the settlement stands as the most significant compliance event in the company's history and is a material fact for any woman evaluating whether to hand over a credit card.

What Noom Actually Sells

Noom sells three overlapping products:

• The behavioral app. Daily color-coded food logging, psychology lessons adapted from cognitive-behavioral therapy (CBT) and acceptance and commitment therapy (ACT), a human coach accessible via in-app chat, and a peer group.
• Noom Med. A telehealth layer, launched in 2023, through which licensed clinicians can prescribe FDA-approved GLP-1 receptor agonists (currently semaglutide and liraglutide) and other weight-related medications after a clinical intake.
• Noom Mood. A mental health app product, separate from weight loss, which this article does not address.

The FTC Settlement and What It Means for You

The FTC action against Noom specifically cited auto-enrollment into paid subscriptions after free trials, difficulty canceling, and charges to consumers who believed they had canceled. The $62 million fund was used to refund affected customers. If you sign up, read the cancellation terms before entering payment information and screenshot confirmation of any cancellation.

The Clinical Evidence Base: What Is Actually Published

Noom's marketing leans heavily on language about being "clinically proven." The peer-reviewed record tells a more modest story.

The One Published Noom Outcomes Study

The most-cited independent study of Noom's app is Chin et al. (2016), published in Scientific Reports. It was a prospective cohort study of 35,921 Noom users who logged food for at least one day over an 18-month observation window. Mean weight loss across completers was 7.3 kg (roughly 16 pounds). The study was not a randomized controlled trial, had no control arm, and the sample skewed heavily toward users who were already engaged. Dropout was not analyzed as an intention-to-treat population.

A smaller pilot RCT, Michaelides et al. (2016), examined 43 participants over 8 weeks and found the Noom group lost significantly more weight than controls. With n=43 and an 8-week window, generalizability is limited.

There is no published long-term RCT of Noom's app in women specifically, in perimenopausal women, or in women with polycystic ovary syndrome (PCOS). The evidence gap is real, and Noom's promotional language does not always make this clear.

GLP-1 Evidence Is Stronger, But Belongs to the Drugs, Not the App

The drugs Noom Med can prescribe, particularly semaglutide, have a strong independent evidence base. The STEP 1 trial (Wilding et al., NEJM, 2021) showed that once-weekly subcutaneous semaglutide 2.4 mg produced a mean 14.9% body weight reduction over 68 weeks versus 2.4% for placebo, in adults with overweight or obesity without diabetes. Approximately 67% of participants in STEP 1 were women, making the data reasonably applicable.

The evidence for semaglutide is the evidence for semaglutide. It does not transfer to the Noom app itself.

Sex-Specific Physiology: How Hormones Change the Weight Picture

Women's weight regulation is not simply a smaller version of men's. Estrogen, progesterone, and androgens interact directly with hypothalamic appetite centers and adipose tissue distribution. This matters for how you interpret any weight-loss program's results.

Reproductive Years

During the menstrual cycle, progesterone rise in the luteal phase (days 14 to 28) increases basal metabolic rate by roughly 100 to 300 kcal/day while also increasing appetite, particularly for calorie-dense foods. A food-logging app that does not account for cycle phase may make a woman feel she is "failing" when she is simply in luteal phase.

Noom's food logging does not integrate menstrual cycle tracking. This is an omission worth knowing.

PCOS

Women with PCOS have insulin resistance as a core feature, independent of BMI. Approximately 70 to 80% of women with PCOS have some degree of insulin resistance. Behavioral coaching alone produces modest, real results in PCOS, but GLP-1 receptor agonists have emerging evidence specifically in this group. A 2022 systematic review in Fertility & Sterility found that GLP-1 agonists improved weight, androgen levels, and menstrual regularity in women with PCOS. If you have PCOS, the GLP-1 prescribing arm of Noom Med may be more relevant than the app alone.

Perimenopause and Postmenopause

The menopausal transition shifts fat distribution toward visceral adiposity and reduces insulin sensitivity, independent of caloric intake. A 2023 statement from The Menopause Society notes that standard caloric restriction programs produce smaller absolute weight loss in postmenopausal women compared to premenopausal women, partly due to loss of estrogen's effect on leptin signaling.

Noom's coaching curriculum does not include menopause-specific content. If you are in perimenopause or postmenopause, you may benefit from a program that addresses menopausal metabolic changes directly, or from combining Noom with menopause-specific clinical care.

Noom Med and GLP-1 Prescribing: Regulation and Safety

Noom Med operates as a telehealth prescriber under the same regulatory framework as other direct-to-consumer telehealth platforms. Prescribing clinicians must be licensed in your state. Prescriptions must follow FDA-approved indications or, for compounded versions, applicable pharmacy regulations. This is the same framework under which Hims/Hers, Found, Ro, and similar competitors operate.

What Noom Med Can Prescribe

As of mid-2025, Noom Med's reported formulary for weight management includes:

• Semaglutide injection (Wegovy, FDA-approved for obesity; Ozempic, FDA-approved for type 2 diabetes)
• Liraglutide injection (Saxenda, FDA-approved for obesity)
• Oral semaglutide (Rybelsus, approved for type 2 diabetes; off-label for weight management)
• Bupropion/naltrexone (Contrave)
• Topiramate-containing combinations in some cases

Formulary availability depends on your state, clinical intake findings, and insurance status.

Compounded Semaglutide: A Specific Safety Concern

During the semaglutide shortage period (2022 to 2024), many telehealth platforms including Noom Med offered compounded semaglutide from 503B outsourcing facilities. The FDA has repeatedly issued warnings about compounded semaglutide products, citing risks from incorrect dosing, non-sterile preparation, and the use of semaglutide sodium rather than the base form used in FDA-approved products. Ask Noom Med directly whether any medication they send is compounded or FDA-approved branded product before you accept a prescription.

Pregnancy, Lactation, and Contraception: Required Reading

GLP-1 receptor agonists are contraindicated in pregnancy. This is not a precautionary hedge. Animal studies of semaglutide showed fetal harm at doses below human therapeutic exposure, and the FDA label for Wegovy states: "Discontinue Wegovy at least 2 months before a planned pregnancy." The drug's half-life means it persists in your system for approximately 5 weeks after the last dose; the 2-month washout is intentional.

If You Are Pregnant

Do not take any GLP-1 agonist. If you become pregnant while on semaglutide or liraglutide, stop the medication immediately and contact your obstetric provider. ACOG does not endorse weight-loss medication use during pregnancy; weight management in pregnancy focuses on gestational weight gain guidelines, not active loss.

If You Are Breastfeeding

There are no adequate human data on GLP-1 agonist transfer into breast milk. The FDA label for semaglutide advises against use during breastfeeding due to potential risk to the infant. Until human lactation data exist, avoidance is the standard recommendation.

Contraception Requirement

Because GLP-1 medications are contraindicated in pregnancy and require a 2-month washout before conception, any woman of reproductive age taking these drugs should use reliable contraception throughout treatment. One additional consideration: rapid weight loss from GLP-1s may increase progesterone sequestration in shrinking adipose tissue, potentially affecting systemic hormonal contraceptive levels. The data are preliminary, but a 2023 analysis suggested women on oral contraceptives who also took semaglutide had measurable changes in contraceptive hormone exposure. Discuss backup contraception with your prescriber.

Postpartum

If you are postpartum and not breastfeeding, you may be a candidate for GLP-1 therapy after your OB clears you, typically no earlier than 6 weeks postpartum. Postpartum weight retention is common; approximately 20% of women retain more than 5 kg one year after delivery. Noom's behavioral coaching may be appropriate postpartum; Noom Med's GLP-1 prescribing should be discussed with your provider given postpartum hormonal changes and breastfeeding status.

Who Noom Is Appropriate For (and Who It Is Not)

Life-Stage Fit

Reproductive years, not pregnant, not trying to conceive. Noom's behavioral app is appropriate. Noom Med's GLP-1 option is available if you meet eligibility criteria (generally BMI >30, or BMI >27 with a weight-related comorbidity) and are using reliable contraception.

Trying to conceive. The behavioral app is fine. GLP-1 medications should be stopped at least 2 months before any attempt to conceive, per FDA labeling.

Pregnant. GLP-1 medications are contraindicated. The behavioral app's food-logging approach is not designed for pregnancy nutrition needs and is not a substitute for prenatal dietary guidance from a registered dietitian.

Postpartum, breastfeeding. GLP-1 medications are not recommended. The app may suit some users but does not include postpartum-specific coaching.

Perimenopause and postmenopause. The app works as a general behavioral tool but lacks menopause-specific content. Noom Med's GLP-1 option has physiologic relevance given menopausal metabolic changes; a 2022 paper in Menopause noted that postmenopausal women achieved clinically meaningful weight loss with GLP-1 agonists and that visceral fat reduction may have cardiovascular benefit in this group.

Conditions Where Noom Med's GLP-1 Arm Has Specific Relevance

• PCOS with insulin resistance. GLP-1 agents address the metabolic root of PCOS-associated weight gain.
• Prediabetes or type 2 diabetes. Semaglutide has a primary indication in type 2 diabetes and demonstrated cardiovascular benefit in the SUSTAIN-6 trial.
• Obesity with hypertension or dyslipidemia. Weight loss of 5 to 10% produces measurable blood pressure and lipid improvements.

Who Should Look Elsewhere

• Women with a personal or family history of medullary thyroid carcinoma or MEN2, because GLP-1 agonists carry an FDA black-box warning for thyroid C-cell tumors in rodents and are contraindicated in these conditions.
• Women with a history of pancreatitis.
• Women who want in-person support, metabolic testing, or a program specifically designed for menopause physiology.
• Women who cannot afford the combined cost of app plus medication, as the total out-of-pocket can exceed $400 to $500 per month without insurance coverage.

Noom vs. Alternatives: An Honest Comparison

Women evaluating Noom typically compare it to WeightWatchers (WW), Found, Calibrate, Ro Body, Sequence (now part of WW), and traditional in-person programs.

WeightWatchers / WW. Points-based food tracking with in-person or virtual workshops. WW has decades of published data, including a 2015 RCT in Lancet (Jolly et al.) showing WW produced greater weight loss than brief GP advice at 12 months. WW also now offers GLP-1 prescribing through its Sequence acquisition. WW does not have menopause-specific programming either.

Found and Calibrate. Both are GLP-1-forward telehealth platforms that pair medication with coaching. Calibrate's original 12-month model included quarterly video visits with physicians; its evidence base is similarly limited to observational data. Found also includes non-GLP-1 medication options.

Ro Body. GLP-1 prescribing with an app; lighter coaching component than Noom.

The honest summary: no direct-to-consumer behavioral weight-loss app, including Noom, has published an RCT with a sample size and duration that would satisfy an independent evidence review for women across life stages. The GLP-1 drugs themselves do have that evidence. The differentiator is coaching quality, user experience, prescribing access, cost, and customer-service practices, not comparative clinical trial data.

Noom's Coaching Model: What You Actually Get

Noom's coaching is asynchronous text-based chat with a human coach. Coaches are trained by Noom and are not licensed clinicians. They cannot provide medical advice, adjust prescriptions, or diagnose conditions. Response times vary; some users report same-day responses, others report delays of 24 to 48 hours.

The psychology curriculum draws on CBT and ACT principles that do have independent evidence for behavioral change. A 2021 Cochrane review on psychological interventions for weight management found that CBT-based programs produced modest but statistically significant weight loss compared to no treatment at 12 months. The Cochrane review did not assess Noom specifically.

The food color-coding system (green, yellow, red) is a simplified nutrient-density framework. Registered dietitians have noted it can be useful as a starting heuristic but may be overly reductive for women with complex nutritional needs, including those recovering from disordered eating, those in pregnancy, or those managing PCOS with carbohydrate sensitivity.

User Experience and Real-World Reviews

Noom has a mixed review profile across platforms. On the Apple App Store it holds a rating of approximately 4.6 out of 5 based on hundreds of thousands of reviews. On Trustpilot, ratings are more variable, with a significant proportion of 1-star reviews specifically citing billing and cancellation difficulties, consistent with the FTC complaint.

Common positive themes from women users include finding the psychological framing helpful, appreciating a non-diet "relationship with food" emphasis, and valuing the structure the app provides.

Common negative themes include coach response delays, feeling the coaching was generic, difficulty canceling, and frustration that the program did not account for hormonal fluctuations or menopause.

Cost Breakdown

Noom's pricing has changed repeatedly. As of mid-2025:

• The behavioral app alone costs approximately $60 to $80 per month, depending on subscription length purchased.
• Noom Med adds medication cost on top. GLP-1 medications without insurance can range from $900 to $1,400 per month for branded Wegovy or Saxenda. Compounded semaglutide, where still available, has ranged from $250 to $400 per month.
• Some insurance plans cover GLP-1 medications prescribed through telehealth; coverage varies significantly by plan.

The total real-world cost for Noom app plus branded GLP-1 without insurance can exceed $1,000 to $1,500 per month. This is a material consideration and one Noom's marketing does not highlight prominently.